2022 Active Pharmaceutical Ingredient (API) Market Report & CDMO Pricing Study

2022 Active Pharmaceutical Ingredient (API) Market Report & CDMO Pricing Study

Order now and learn more about:

  • Measure your pricing against competitors across relevant line items
  • Perform due diligence when investing or choosing a manufacturing partner
  • A comprehensive landscape of top 30 API CDMOs
  • Understand important considerations for buyers of outsourced services from KOLs
  • Projections on ongoing growth of branded and generic API markets
  • Analysis of new technologies in development and Industry 4.0

2022 API Report Brings Value to Innovators, CDMOs, & PE Investors

For Innovators Seeking Due Diligence Information and CDMOs and Investors Looking for Benchmarking and Peer Comparison

Nice Insight has begun compiling primary and secondary data to create a comprehensive report on the dynamic development and manufacturing market for active pharmaceutical ingredients. The report will explore innovations in modalities and synthesis systems, manufacturing equipment and processes, automation, and analytics for APIs, including next-generation APIs, highly potent and controlled substances, and generics. The report will include a proprietary pricing study providing pricing data for a full range of line items associated with outsourced API development and manufacturing services.

What You Get With the Report

  • Current 2022 pricing benchmarks based on actual quotes given by providers for all typical service line items within API programs.
  • Ability to measure whether your pricing levels are right against high, low, and median pricing in the marketplace.
  • A comprehensive view of the competitive landscape with a directory of the Top 30 API CDMOs across major regions today, including capabilities, capacity, proprietary technologies, and locations.
  • Input from subject matter experts (SMEs) from CDMOs and buyers of outsourced services.
  • Projections on ongoing growth of the branded and generic API markets.
  • Analysis of new technologies in development and Industry 4.0.